MCID: CLN019
MIFTS: 62

Colonic Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Colonic Disease

MalaCards integrated aliases for Colonic Disease:

Name: Colonic Disease 12 15
Colonic Diseases 56 44 45 74
Colon Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5353
MeSH 45 D003108
UMLS 74 C0009373

Summaries for Colonic Disease

MedlinePlus : 44 Your colon, also known as the large intestine, is part of your digestive system. It's a long, hollow tube at the end of your digestive tract where your body makes and stores stool. Many disorders affect the colon's ability to work properly. Some of these include Colorectal cancer Colonic polyps - extra tissue growing in the colon that can become cancerous Ulcerative colitis - ulcers of the colon and rectum Diverticulitis - inflammation or infection of pouches in the colon Irritable bowel syndrome - an uncomfortable condition causing abdominal cramping and other symptoms Treatment for colonic diseases varies greatly depending on the disease and its severity. Treatment may involve diet, medicines and in some cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Colonic Disease, also known as colonic diseases, is related to megacolon and ulcerative colitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Colonic Disease is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Bisacodyl and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 The large intestine, also known as the large bowel, is the last part of the gastrointestinal tract and... more...

Related Diseases for Colonic Disease

Diseases related to Colonic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 megacolon 31.9 EDN3 EDNRB RET SOX10
2 ulcerative colitis 30.3 CTNNB1 MLH1 MSH2 NOD2
3 colitis 30.3 AKT1 CTNNB1 MLH1 NOD2 PTGS2
4 familial adenomatous polyposis 29.6 CTNNB1 KRAS MLH1 MSH2 MYC PTGS2
5 pancreatic cancer 29.5 AKT1 CASP3 CEACAM5 CTNNB1 HRAS KRAS
6 functional colonic disease 12.1
7 diverticulitis of colon 10.8
8 actinic cheilitis 10.6 MSH2 TP53
9 benign struma ovarii 10.6 HRAS RET
10 protoplasmic astrocytoma 10.6 PTGS2 TP53
11 adenosquamous colon carcinoma 10.6 MLH1 MSH2
12 short-rib thoracic dysplasia 4 with or without polydactyly 10.6 CASP3 TP53
13 mucinous adenofibroma 10.6 CEACAM5 ESR1
14 malignant spiradenoma 10.6 CEACAM5 TP53
15 urachal adenocarcinoma 10.6 CEACAM5 KRAS
16 pharynx squamous cell carcinoma 10.6 AKT1 CASP3
17 intrahepatic cholangiocarcinoma 10.6 CTNNB1 KRAS TP53
18 renal cell carcinoma, papillary, 1 10.6 HRAS MSH2 TP53
19 hepatoblastoma 10.6 CASP3 CTNNB1 TP53
20 endometrial clear cell adenocarcinoma 10.6 CTSD ESR1
21 constipation 10.5 EDN3 EDNRB RET
22 gastric adenosquamous carcinoma 10.5 DDX53 STAT3 TP53
23 female reproductive endometrioid cancer 10.5 CTNNB1 ESR1 TP53
24 sebaceous adenoma 10.5 ESR1 MLH1 MSH2
25 nasal cavity adenocarcinoma 10.5 HRAS KRAS TP53
26 rare adenocarcinoma of the breast 10.5 AKT1 KRAS TP53
27 sigmoid neoplasm 10.5 CEACAM5 HRAS KRAS
28 lower lip cancer 10.5 CASP3 MLH1 MSH2
29 apocrine adenoma 10.5 CEACAM5 HRAS KRAS
30 liver angiosarcoma 10.5 HRAS KRAS TP53
31 uterine corpus cancer 10.5 ESR1 MYC TP53
32 anal squamous cell carcinoma 10.5 AKT1 MLH1 TP53
33 melanocytic nevus syndrome, congenital 10.5 HRAS MLH1 MSH2
34 waardenburg syndrome type 4 10.5 EDN3 EDNRB SOX10
35 ampulla of vater cancer 10.5 HRAS KRAS TP53
36 aggressive digital papillary adenocarcinoma 10.5 CEACAM5 HRAS KRAS
37 adenosquamous lung carcinoma 10.5 HRAS KRAS RET
38 breast ductal carcinoma 10.5 CTNNB1 CTSD ESR1 TP53
39 prostate squamous cell carcinoma 10.5 CEACAM5 HRAS TP53
40 richter's syndrome 10.5 MLH1 MYC TP53
41 barrett's adenocarcinoma 10.5 KRAS PTGS2 TP53
42 waardenburg syndrome, type 4b 10.5 EDN3 EDNRB SOX10
43 cochlear disease 10.5 EDN3 EDNRB SOX10
44 fallopian tube carcinoma 10.5 ESR1 MYC TP53
45 cerebral primitive neuroectodermal tumor 10.5 MSH2 MYC TP53
46 keratoacanthoma 10.5 MLH1 MSH2 TP53
47 mixed cell type cancer 10.5 CEACAM5 HRAS TP53
48 carcinosarcoma 10.5 CTNNB1 HRAS KRAS TP53
49 cecum adenocarcinoma 10.5 HRAS KRAS MLH1 MSH2
50 lung benign neoplasm 10.5 HRAS KRAS TP53

Graphical network of the top 20 diseases related to Colonic Disease:



Diseases related to Colonic Disease

Symptoms & Phenotypes for Colonic Disease

UMLS symptoms related to Colonic Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Colonic Disease according to GeneCards Suite gene sharing:

27 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.61 HRAS KRAS
2 Decreased viability GR00106-A-0 10.61 KRAS
3 Decreased viability GR00221-A-1 10.61 AKT1 ESR1 HRAS KRAS RET MYC
4 Decreased viability GR00221-A-2 10.61 AKT1 ESR1 HRAS KRAS RET
5 Decreased viability GR00221-A-3 10.61 AKT1 HRAS MYC
6 Decreased viability GR00221-A-4 10.61 AKT1 ESR1 RET
7 Decreased viability GR00231-A 10.61 RET
8 Decreased viability GR00301-A 10.61 KRAS RET
9 Decreased viability GR00381-A-1 10.61 KRAS
10 Decreased viability GR00402-S-2 10.61 AKT1 ESR1 HRAS KRAS RET MYC
11 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.3 SOX10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.3 CTNNB1 KRAS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.3 CTNNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.3 SOX10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.3 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.3 AKT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.3 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.3 NOD2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.3 AKT1 CTNNB1 KRAS NOD2 SOX10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.3 NOD2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.3 NOD2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.3 NOD2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.3 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.3 CTNNB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.3 NOD2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.3 KRAS
27 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.3 SOX10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.3 NOD2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.3 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.3 NOD2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.3 CTNNB1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.3 CTNNB1 KRAS SOX10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.3 AKT1 KRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.3 KRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.3 CTNNB1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.3 SOX10
37 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.3 AKT1 SOX10
38 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.3 CTNNB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.3 CTNNB1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.3 AKT1 CTNNB1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.3 SOX10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.3 AKT1 SOX10
43 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.3 KRAS
44 Decreased cell migration GR00055-A-1 9.65 AKT1 CTNNB1 CTSD HRAS KRAS
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 AKT1 CASP3 MLH1 NOD2 SOX10 TP53
46 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 AKT1 CASP3 MLH1 MYC NOD2 SOX10

MGI Mouse Phenotypes related to Colonic Disease:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.54 CASP3 CTNNB1 CTSD EDN3 EDNRB ESR1
2 cellular MP:0005384 10.53 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
3 behavior/neurological MP:0005386 10.51 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
4 homeostasis/metabolism MP:0005376 10.5 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
5 endocrine/exocrine gland MP:0005379 10.47 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
6 growth/size/body region MP:0005378 10.47 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
7 mortality/aging MP:0010768 10.46 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
8 hematopoietic system MP:0005397 10.45 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
9 integument MP:0010771 10.45 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
10 immune system MP:0005387 10.43 AKT1 CASP3 CTNNB1 CTSD EDNRB ESR1
11 cardiovascular system MP:0005385 10.41 AKT1 CASP3 CTNNB1 EDNRB ESR1 HRAS
12 embryo MP:0005380 10.38 AKT1 CTNNB1 EDN3 EDNRB ESR1 KRAS
13 nervous system MP:0003631 10.36 AKT1 CASP3 CTNNB1 CTSD EDN3 EDNRB
14 neoplasm MP:0002006 10.32 AKT1 CTNNB1 EDNRB ESR1 HRAS KRAS
15 muscle MP:0005369 10.24 AKT1 CASP3 CTNNB1 EDNRB ESR1 KRAS
16 craniofacial MP:0005382 10.22 CASP3 CTNNB1 EDNRB HRAS KRAS MYC
17 limbs/digits/tail MP:0005371 10.14 CTNNB1 EDNRB ESR1 KRAS MYC RET
18 normal MP:0002873 10.14 AKT1 CTNNB1 ESR1 HRAS KRAS MYC
19 hearing/vestibular/ear MP:0005377 10.13 CASP3 CTNNB1 CTSD EDNRB KRAS MYC
20 liver/biliary system MP:0005370 10.13 AKT1 CTNNB1 ESR1 KRAS MYC PTGS2
21 no phenotypic analysis MP:0003012 10.13 CASP3 CTNNB1 ESR1 HRAS KRAS MYC
22 renal/urinary system MP:0005367 10.02 CASP3 CTNNB1 EDNRB ESR1 HRAS KRAS
23 reproductive system MP:0005389 10 AKT1 CASP3 CTNNB1 ESR1 KRAS MLH1
24 pigmentation MP:0001186 9.97 CASP3 CTNNB1 EDN3 EDNRB KRAS MYC
25 respiratory system MP:0005388 9.97 AKT1 CASP3 CTNNB1 EDNRB ESR1 HRAS
26 skeleton MP:0005390 9.73 AKT1 CASP3 CTNNB1 EDNRB ESR1 HRAS
27 vision/eye MP:0005391 9.28 CASP3 CTNNB1 CTSD EDNRB KRAS MLH1

Drugs & Therapeutics for Colonic Disease

Drugs for Colonic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1036)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bisacodyl Approved Phase 4,Not Applicable 603-50-9
2
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
3
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
4
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6 774
5
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
6
Pentoxifylline Approved, Investigational Phase 4,Phase 2 6493-05-6 4740
7
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
9
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
10
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1401-55-4
11
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
12
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
13
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
14
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
15
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 1,Not Applicable 76-42-6 5284603
16
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
17
Bupivacaine Approved, Investigational Phase 4,Phase 2,Not Applicable 38396-39-3, 2180-92-9 2474
18
Ketorolac Approved Phase 4,Not Applicable 74103-06-3, 66635-83-4 3826
19
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable,Early Phase 1 437-38-7 3345
21
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
22
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
23
Morphine Approved, Investigational Phase 4,Phase 3,Not Applicable 57-27-2 5288826
24
Orphenadrine Approved Phase 4 83-98-7 4601
25
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
26
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
27
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
28
Methadone Approved, Illicit Phase 4 76-99-3 4095
29
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 17902-23-7 5386
30
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
31
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
32
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112887-68-0 104758
33
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
34
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
35 Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
36
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 114-07-8 441411 12560
37
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
38
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
39
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
40
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
41
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
42
Phylloquinone Approved, Investigational Phase 4,Phase 2 84-80-0
43 Menaquinone Approved, Investigational Phase 4,Phase 2 1182-68-9
44
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
45
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7553-56-2 807
46
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
47
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
48
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 2078-54-8 4943
49
Pancrelipase Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 53608-75-6
50
Loperamide Approved Phase 4,Phase 2,Phase 3,Not Applicable 53179-11-6 3955

Interventional clinical trials:

(show top 50) (show all 5616)
# Name Status NCT ID Phase Drugs
1 Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients Unknown status NCT01853709 Phase 4 Polyethylene glycol (PEG);Bisacodyl
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
4 Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial Unknown status NCT01908465 Phase 4 Ebastine;Placebo
5 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
6 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
7 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
8 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
9 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
10 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
11 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
12 Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
13 Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
14 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
15 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
16 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
17 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
18 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
19 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
20 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
21 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
22 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
23 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
24 Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
25 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Unknown status NCT02383797 Phase 4
26 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
27 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
28 Intravenous Iron for Correction of Anaemia After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
29 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
30 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
31 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
32 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
33 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
34 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
35 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
36 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
37 Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Unknown status NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
38 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
39 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
40 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
41 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
42 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
43 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
44 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
45 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
46 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
47 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
48 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
49 Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis Unknown status NCT00097734 Phase 4 ertapenem
50 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4

Search NIH Clinical Center for Colonic Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: colonic diseases

Genetic Tests for Colonic Disease

Anatomical Context for Colonic Disease

MalaCards organs/tissues related to Colonic Disease:

42
Colon, Liver, Testes, Lung, Breast, T Cells, Lymph Node

Publications for Colonic Disease

Articles related to Colonic Disease:

(show top 50) (show all 121)
# Title Authors Year
1
Microscopic / "Backwash" Ileitis and its Association with Colonic Disease in New Onset Pediatric Ulcerative Colitis. ( 30676522 )
2019
2
Should We Divide Crohn's Disease Into Ileum-dominant and Isolated Colonic Diseases? ( 31009791 )
2019
3
Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. ( 29361096 )
2018
4
Pancreatic cancer presenting as colonic disease. A rare case report. ( 29454229 )
2018
5
The Growing Utilization of Laparoscopy in Emergent Colonic Disease. ( 29391097 )
2017
6
Melatonin's role as a co-adjuvant treatment in colonic diseases: A review. ( 27919824 )
2017
7
Advances in colonic disease: some light at the end of the tunnel at the end of the light! ( 26628103 )
2016
8
Colonic disease site and perioperative complications predict need for later intestinal interventions following intestinal resection in pediatric Crohn's disease. ( 26653943 )
2016
9
Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. ( 26937622 )
2016
10
Single-incision versus standard multi-incision laparoscopic colectomy in patients with malignant or benign colonic disease: a systematic review, meta-analysis and assessment of the evidence. ( 27756272 )
2016
11
Emerging Roles of Hydrogen Sulfide in Inflammatory and Neoplastic Colonic Diseases. ( 27199771 )
2016
12
Raman Spectroscopy for the Endoscopic Diagnosis of Esophageal, Gastric, and Colonic Diseases. ( 27653440 )
2016
13
PillCam colon capsule endoscopy (PCCE) in colonic diseases. ( 27668227 )
2016
14
Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. ( 27672289 )
2016
15
Erratum to PillCam colon capsule endoscopy (PCCE) in colonic diseases. ( 27761464 )
2016
16
Robotic versus laparoscopic surgery for colonic disease: a meta-analysis of postoperative variables. ( 25847139 )
2015
17
Concomitant colonic disease (Montreal L3) and re-resectional surgery are predictors of clinical recurrence following ileocolonic resection for Crohn's disease. ( 26291699 )
2015
18
Feasibility of real-time strain elastography in colonic diseases. ( 25368693 )
2014
19
Curcumin: a boon to colonic diseases. ( 23768171 )
2013
20
Enteric infection with Citrobacter rodentium induces coagulative liver necrosis and hepatic inflammation prior to peak infection and colonic disease. ( 22427959 )
2012
21
The colonic microbiota and colonic disease. ( 22941733 )
2012
22
Is proliferative colonic disease presentation changing? ( 23236236 )
2012
23
Novel prodrugs for the treatment of colonic diseases based on 5-aminosalicylic acid, 4'-geranyloxyferulic acid, and auraptene: biological activities and analytical assays. ( 22283649 )
2012
24
Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease. ( 21825842 )
2011
25
Design and in vitro evaluation of a bipolymeric delivery device for the amelioration of colonic diseases using a popular glucocorticoid as a model drug. ( 21928719 )
2011
26
Advanced diagnostic imaging in colonic disease. ( 20190723 )
2010
27
Emergency laparoscopic surgery for right colonic diseases with peritonitis. ( 20687816 )
2010
28
European Society of Gastrointestinal Endoscopy (ESGE): recommendations (2009) on clinical use of video capsule endoscopy to investigate small-bowel, esophageal and colonic diseases. ( 20195992 )
2010
29
Colonic perforation during barium enema in a patient without known colonic disease: a case report. ( 19918538 )
2009
30
Third ESPGHAN Capri Meeting, "Colonic Diseases: Problems and Progress", in Capri, Italy, April 2-4, 2009. Introduction. ( 19300121 )
2009
31
Balsalazide in treating colonic diseases. ( 19708827 )
2009
32
Acute colonic disease: how to image in emergency. ( 17174054 )
2007
33
Biochemical and immunohistochemical characterisation of mucins in 8 cases of colonic disease--a pilot study. ( 17969773 )
2007
34
Colonic diseases: the value of US examination. ( 17889476 )
2007
35
Colonic perforation at CT colonography in a patient without known colonic disease. ( 16357389 )
2006
36
Death from colonic disease in epidermolysis bullosa dystrophica. ( 16480504 )
2006
37
Cerebrospinal fluid polyamine levels in patients with colonic disease. ( 12567356 )
2003
38
Halo sign: useful CT sign for differentiating benign from malignant colonic disease. ( 12662952 )
2003
39
Coprocytobiology: on the nature of cellular elements from stools in the pathophysiology of colonic disease. ( 12702972 )
2003
40
Prebiotics: actual and potential effects in inflammatory and malignant colonic diseases. ( 12913677 )
2003
41
The course of colonic disease in ulcerative colitis patients with primary sclerosing cholangitis. ( 16378294 )
2002
42
Interleukin-2-Deficient mice: effect on cytokines and inflammatory cells in chronic colonic disease. ( 11913411 )
2002
43
Development of a chronic colonic intubation model in rats for the study of luminal factors in colonic diseases. ( 11852341 )
2002
44
Apoptotic colonic disease: a new entity in a primate. ( 11286126 )
2001
45
Variability in the severity of colonic disease in familial adenomatous polyposis results from differences in tumour initiation rather than progression and depends relatively little on patient age. ( 11559652 )
2001
46
Investigation of colonic disease. ( 11103279 )
2000
47
Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. ( 9923929 )
1999
48
Psoas abscesses complicating colonic disease: imaging and therapy. ( 10645182 )
1999
49
Nitric oxide and inflammatory bowel disease: evidence for local intestinal production in children with active colonic disease. ( 9443117 )
1998
50
Does sucrase deficiency in black South Africans protect against colonic disease? ( 9449875 )
1998

Variations for Colonic Disease

Expression for Colonic Disease

Search GEO for disease gene expression data for Colonic Disease.

Pathways for Colonic Disease

Pathways related to Colonic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 AKT1 CASP3 CTNNB1 CTSD HRAS KRAS
2
Show member pathways
13.96 AKT1 CASP3 CTNNB1 ESR1 HRAS KRAS
3
Show member pathways
13.78 AKT1 CASP3 EDNRB HRAS KRAS MYC
4
Show member pathways
13.45 AKT1 CASP3 HRAS KRAS MYC NOD2
5
Show member pathways
13.13 AKT1 CTSD EDNRB ESR1 HRAS KRAS
6
Show member pathways
13.13 AKT1 CASP3 CTNNB1 HRAS KRAS STAT3
7
Show member pathways
13.1 AKT1 CASP3 CTNNB1 HRAS KRAS MYC
8
Show member pathways
13.05 AKT1 CASP3 CTNNB1 HRAS KRAS TP53
9
Show member pathways
13.05 AKT1 CASP3 CTNNB1 HRAS KRAS MYC
10
Show member pathways
13.03 AKT1 CASP3 EDN3 EDNRB HRAS KRAS
11
Show member pathways
13.03 AKT1 HRAS KRAS MLH1 MSH2 PTGS2
12
Show member pathways
13.01 AKT1 CTNNB1 HRAS KRAS PTGS2 STAT3
13
Show member pathways
12.94 AKT1 CASP3 CTSD HRAS KRAS MYC
14 12.88 AKT1 CASP3 HRAS KRAS MYC TP53
15
Show member pathways
12.87 AKT1 HRAS KRAS MYC STAT3
16
Show member pathways
12.85 AKT1 CTNNB1 ESR1 HRAS KRAS MLH1
17
Show member pathways
12.84 AKT1 EDNRB HRAS KRAS PTGS2
18
Show member pathways
12.81 AKT1 ESR1 HRAS KRAS STAT3 TP53
19
Show member pathways
12.8 CASP3 ESR1 MSH2 MYC TP53
20
Show member pathways
12.8 AKT1 CASP3 HRAS KRAS STAT3 TP53
21
Show member pathways
12.77 AKT1 CASP3 CTNNB1 HRAS KRAS
22
Show member pathways
12.76 AKT1 CASP3 CTNNB1 ESR1 HRAS KRAS
23
Show member pathways
12.74 AKT1 CASP3 CTNNB1 HRAS KRAS MLH1
24
Show member pathways
12.72 AKT1 HRAS KRAS MYC STAT3 TP53
25
Show member pathways
12.66 AKT1 CTNNB1 HRAS KRAS MSH2 MYC
26 12.62 CASP3 HRAS KRAS MYC PTGS2 STAT3
27
Show member pathways
12.6 AKT1 CASP3 CTNNB1 HRAS KRAS MYC
28
Show member pathways
12.57 AKT1 CASP3 CTNNB1 HRAS KRAS TP53
29
Show member pathways
12.56 AKT1 HRAS KRAS STAT3
30
Show member pathways
12.55 AKT1 CASP3 CTSD ESR1 HRAS KRAS
31 12.54 AKT1 CTNNB1 MYC PTGS2 TP53
32 12.53 AKT1 CASP3 CTNNB1 EDNRB ESR1 HRAS
33
Show member pathways
12.52 AKT1 HRAS KRAS MYC STAT3
34
Show member pathways
12.52 AKT1 HRAS MYC STAT3 TP53
35
Show member pathways
12.5 AKT1 HRAS KRAS PTGS2
36
Show member pathways
12.5 AKT1 CTNNB1 ESR1 HRAS KRAS PTGS2
37 12.49 AKT1 CTNNB1 HRAS KRAS MYC TP53
38
Show member pathways
12.47 AKT1 HRAS KRAS MYC
39
Show member pathways
12.45 AKT1 CTNNB1 HRAS MYC STAT3
40
Show member pathways
12.43 AKT1 HRAS KRAS STAT3
41
Show member pathways
12.43 AKT1 CASP3 PTGS2 STAT3
42
Show member pathways
12.42 AKT1 ESR1 HRAS PTGS2
43 12.42 CASP3 HRAS KRAS STAT3 TP53
44
Show member pathways
12.4 AKT1 HRAS PTGS2 TP53